139
Views
4
CrossRef citations to date
0
Altmetric
Original Research

The Incidence, Characteristics, and Use of Suspected Nephrotoxic Drugs in Elderly Patients with Community-Acquired Acute Kidney Injury

, , , , , , & ORCID Icon show all
Pages 35-42 | Published online: 07 Jan 2021

References

  • Lewington AJ, Cerda J, Mehta RL. Raising awareness of acute kidney injury: a global perspective of a silent killer. Kidney Int. 2013;84(3):457–467. doi:10.1038/ki.2013.15323636171
  • Lafrance JP, Miller DR. Acute kidney injury associates with increased long-term mortality. J Am Soc Nephrol. 2010;21(2):345–352. doi:10.1681/ASN.200906063620019168
  • Clark EG, Hiremath S, Sood MM, et al. WITHDRAWN: death and recovery of kidney function among patients continued on dialysis after discharge from hospital stays complicated by acute kidney injury: a cohort study. Am J Kidney Dis. 2019:. doi:10.1053/j.ajkd.2019.03.429.
  • Wang Y, Wang J, Su T, Qu Z, Zhao M, Yang L. Community-acquired acute kidney injury: a nationwide survey in China. Am J Kidney Dis. 2017;69(5):647–657. doi:10.1053/j.ajkd.2016.10.03428117208
  • Hsu CY, McCulloch CE, Fan D, Ordonez JD, Chertow GM, Go AS. Community-based incidence of acute renal failure. Kidney Int. 2007;72(2):208–212. doi:10.1038/sj.ki.500229717507907
  • Cox ZL, McCoy AB, Matheny ME, et al. Adverse drug events during AKI and its recovery. Clin J Am Soc Nephrol. 2013;8(7):1070–1078. doi:10.2215/CJN.1192111223539228
  • Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122–1137. doi:10.1038/ki.2011.32221918498
  • Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-0000619414839
  • Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-83558716
  • Wonnacott A, Meran S, Amphlett B, Talabani B, Phillips A. Epidemiology and outcomes in community-acquired versus hospital-acquired AKI. Clin J Am Soc Nephrol. 2014;9(6):1007–1014. doi:10.2215/CJN.07920713.24677557
  • Adu D, Okyere P, Boima V, Matekole M, Osafo C. Community-acquired acute kidney injury in adults in Africa. Clin Nephrol. 2016;86:48–52. doi:10.5414/CNP86S12127469159
  • Welch HK, Kellum JA, Kane-Gill SL. Drug-associated acute kidney injury identified in the united states food and drug administration adverse event reporting system database. Pharmacotherapy. 2018;38(8):785–793. doi:10.5414/CNP86S12129883524
  • Levey AS, James MT. Acute kidney injury. Ann Intern Med. 2017;167(9):Itc66–itc80. doi:10.7326/AITC20171107029114754
  • Nash DM, Markle-Reid M, Brimble KS, et al. Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study. Nephrol Dial Transplant. 2019;34(7):1145–1154. doi:10.1093/ndt/gfz06231264694
  • McCullough PA, Choi JP, Feghali GA, et al. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2016;68(13):1465–1473. doi:10.1016/j.jacc.2016.05.09927659469
  • Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv. 2014;7(1):1–9. doi:10.1016/j.jcin.2013.06.01624456715
  • Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385(9982):2047–2056. doi:10.1016/S0140-6736(14)62459-426009228
  • Brar S, Ye F, James MT, Hemmelgarn B, Klarenbach S, Pannu N. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with outcomes after acute kidney injury. JAMA Intern Med. 2018;178(12):1681–1690. doi:10.1001/jamainternmed.2018.474930422153
  • Khan S, Loi V, Rosner MH. Drug-induced kidney injury in the elderly. Drugs Aging. 2017;34(10):729–741. doi:10.1007/s40266-017-0484-428815461
  • Pierson-Marchandise M, Gras V, Moragny J, et al. The drugs that mostly frequently induce acute kidney injury: a case - noncase study of a pharmacovigilance database. Br J Clin Pharmacol. 2017;83(6):1341–1349. doi:10.1111/bcp.1321628002877
  • High KP, Bradley SF, Gravenstein S, et al. Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the infectious diseases society of America. Clin Infect Dis. 2009;48(2):149–171. doi:10.1086/59568319072244
  • Rutter WC, Burgess DR, Talbert JC, Burgess DS. Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: A retrospective cohort analysis. J Hosp Med. 2017;12(2):77–82. doi:10.12788/jhm.268428182801
  • Ong LZ, Tambyah PA, Lum LH, et al. Aminoglycoside-associated acute kidney injury in elderly patients with and without shock. J Antimicrob Chemother. 2016;71(11):3250–3257. doi:10.1093/jac/dkw29627494924
  • Ramos-Martinez A, Vicente-Lopez N, Sanchez-Romero I, et al. Epidemiology and prognosis of candidaemia in elderly patients. Mycoses. 2017;60(12):808–817. doi:10.1111/myc.1267728836309
  • Vanmassenhove J, Kielstein J, Jorres A, Biesen WV. Management of patients at risk of acute kidney injury. Lancet. 2017;389(10084):2139–2151. doi:10.1016/S0140-6736(17)31329-628561005
  • Dharmarajan K, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in older adults. Heart Fail Clin. 2017;13(3):417–426. doi:10.1016/j.hfc.2017.02.00128602363
  • Soto K, Campos P, Pinto I, et al. The risk of chronic kidney disease and mortality are increased after community-acquired acute kidney injury. Kidney Int. 2016;90(5):1090–1099. doi:10.1016/j.kint.2016.07.01827658322